Shares of CytoDyn Inc. (OTCMKTS:CYDY - Get Free Report) passed below its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $0.24 and traded as low as $0.23. CytoDyn shares last traded at $0.24, with a volume of 1,440,438 shares changing hands.
CytoDyn Stock Up 7.1 %
The stock has a market capitalization of $303.67 million, a P/E ratio of -24.64 and a beta of -0.28. The company has a 50 day moving average of $0.24 and a 200-day moving average of $0.17.
CytoDyn Company Profile
(
Get Free Report)
CytoDyn Inc, a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer.
Featured Stories
Before you consider CytoDyn, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CytoDyn wasn't on the list.
While CytoDyn currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
